It is critical to understand the molecular mechanisms of exhibiting enhanced inhibitory effects on NSCLC cells by combination of mTOR and Mnk inhibitors, and which will help us to develop new therapy strategies to overcome resistance in mTOR-targeted cancer therapy. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.